Medium February 7, 2024
The Daily Edition

We all want to know where we come from. If you’ve ever told someone you want to learn more about your ancestry (as I have) they’ll probably point you toward 23andMe, the genetic testing company that went public in 2021 and was briefly valued at $6 billion (or about $1 billion more than what Reddit is eyeing as a valuation for its expected IPO later this year).

It turns out 23andMe is now worth almost $0. I’ve never spit into one of their tubes, but I can see why. Because DNA tests only need to be done once, 23andMe has a business model that doesn’t attract repeat customers. Also, the data isn’t placed in context or paired with genealogical records,...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Insurance, Pharma / Biotech, Precision Medicine
Putting Patients First by Extending the Reach of World-Class Care
Healthcare's most promising tech
AI In Healthcare: A New Era Of Personalized Patient Care
23andMe reports sales decline a day after announcing plans to cut 40% of workforce
Patient-derived organoids: Transforming cancer research and personalized medicine

Share This Article